Teva Pharmaceutical Industries Limited and Walgreens Boots Alliance, Inc.: A Detailed Gross Profit Analysis

Teva vs. Walgreens: A Decade of Profit Dynamics

__timestampTeva Pharmaceutical Industries LimitedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20141105600000021569000000
Thursday, January 1, 20151135600000026753000000
Friday, January 1, 20161185900000029874000000
Sunday, January 1, 20171082500000029162000000
Monday, January 1, 2018829600000030792000000
Tuesday, January 1, 2019753600000028159000000
Wednesday, January 1, 2020772500000026077000000
Friday, January 1, 2021759400000028067000000
Saturday, January 1, 2022697300000028266000000
Sunday, January 1, 2023764600000027072000000
Monday, January 1, 2024806400000026524000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Giants: Teva and Walgreens Boots Alliance

In the ever-evolving pharmaceutical landscape, Teva Pharmaceutical Industries Limited and Walgreens Boots Alliance, Inc. stand as titans. From 2014 to 2023, Walgreens consistently outperformed Teva in gross profit, with Walgreens' profits peaking in 2018 at over 40% higher than Teva's. However, Teva's journey is marked by resilience, maintaining a steady gross profit despite industry challenges. Notably, 2016 was a high point for Teva, with a gross profit of approximately 11.9 billion, before facing a decline. Walgreens, on the other hand, showcased robust growth, with a peak gross profit in 2018, reflecting its strategic market positioning. The data for 2024 is incomplete, hinting at potential shifts in the competitive dynamics. This analysis underscores the importance of strategic agility in the pharmaceutical sector, where market forces and innovation drive success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025